Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA orders ESA labelling changes to narrow use

This article was originally published in Scrip

Executive Summary

The US FDAhas ordered labelling changes for erythropoiesis-stimulating agents (ESAs) to advise against use in patients receiving chemotherapy in the adjuvant setting and place a haemoglobin level ceiling for initiation of treatment. However, the FDA opted not to restrict use of the anaemia treatments in patients according to tumour types, despite a recommendation to the contrary by its oncologic drugs advisory panel.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC001010

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel